Literature DB >> 2251279

Mitochondrial respiratory inhibition by N-methylated beta-carboline derivatives structurally resembling N-methyl-4-phenylpyridine.

R Albores1, E J Neafsey, G Drucker, J Z Fields, M A Collins.   

Abstract

Mitochondrial accumulation and respiratory inhibition are critical steps in the actions of N-methyl-4-phenylpyridinium ion (MPP+), the toxic metabolite of the parkinsonism-inducing agent, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. We examined the respiratory characteristics of 2-methylated beta-carbolines (2-Me beta Cs) and 2-methylated 3,4-dihydro-beta-carbolines (2-MeDH beta Cs), which encompass the MPP+ structure. As indoleamine derivatives, they could have endogenous roles in idiopathic parkinsonism. With rat liver mitochondria, the order for inhibition of NAD(+)-linked O2 consumption (6-min preincubations) was as follows: MPP+ = 2-methylharmine greater than 2-methylharmol = 2-methylharmaline much greater than 2-methylharmalol greater than 2-methylnorharman greater than 6-OH-2-methylharmalan much greater than 2-methylharman. Similar to MPP+, 2-MeDH beta C/2-Me beta C inhibition was potentiated by tetraphenylboron and reversed by dinitrophenol, consistent with the involvement of cationic forms. However, the participation of neutral forms was indicated by the 2-MeDH beta C/2-Me beta C inhibitory time courses, which were unlike MPP+. The neutral forms probably arise via indolic nitrogen deprotonation because the characteristics of a cationic beta-carboline that cannot N-deprotonate, 2,9-dimethylnorharman, mirrored MPP+ rather than 2-Me beta Cs. Succinate-supported respiration was also significantly blocked by 2-MeDH beta Cs/2-Me beta Cs, but results with tetraphenylboron and 2,9-dimethylnorharman indicated that cationic forms were less important than in the inhibition of NAD(+)-linked respiration. We suggest that the relatively potent inhibition by certain 2-MeDH beta Cs/2-Me beta Cs involves neutral forms for passive mitochondrial entry and cationic as well as neutral forms that act at several respiratory sites. Respiratory inhibition could reasonably underlie the reported neurotoxicity of 2-Me beta Cs.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2251279      PMCID: PMC55166          DOI: 10.1073/pnas.87.23.9368

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  33 in total

1.  Endogenously formed norharman (beta-carboline) in platelet rich plasma obtained from porphyric rats.

Authors:  M J Schouten; J Bruinvels
Journal:  Pharmacol Biochem Behav       Date:  1986-05       Impact factor: 3.533

2.  Methyltetrahydro-beta-carbolines and Parkinson's disease.

Authors:  S Ohkubo; T Hiraro; K Oka
Journal:  Lancet       Date:  1985-06-01       Impact factor: 79.321

3.  Does an endogenous methylpyridinium analogue cause Parkinson's disease?

Authors:  B Testa; R Naylor; B Costall; P Jenner; C D Marsden
Journal:  J Pharm Pharmacol       Date:  1985-09       Impact factor: 3.765

4.  Beta-carboline analogues of N-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP): endogenous factors underlying idiopathic parkinsonism?

Authors:  M A Collins; E J Neafsey
Journal:  Neurosci Lett       Date:  1985-04-09       Impact factor: 3.046

5.  Uptake of the neurotoxin 1-methyl-4-phenylpyridine (MPP+) by mitochondria and its relation to the inhibition of the mitochondrial oxidation of NAD+-linked substrates by MPP+.

Authors:  R R Ramsay; J I Salach; T P Singer
Journal:  Biochem Biophys Res Commun       Date:  1986-01-29       Impact factor: 3.575

6.  Rapid hydroxylation of methtryptoline (1-methyltetrahydro-beta-carboline) in rat: identification of metabolites by chiral gas chromatography-mass spectrometry.

Authors:  O Beck; K F Faull; D B Repke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-07       Impact factor: 3.000

7.  Metabolism of the beta-carbolines, harmine and harmol, by liver microsomes from phenobarbitone- or 3-methylcholanthrene-treated mice. Identification and quantitation of two novel harmine metabolites.

Authors:  D J Tweedie; M D Burke
Journal:  Drug Metab Dispos       Date:  1987 Jan-Feb       Impact factor: 3.922

8.  Inhibition of NADH oxidation by pyridine derivatives.

Authors:  R R Ramsay; K A McKeown; E A Johnson; R G Booth; T P Singer
Journal:  Biochem Biophys Res Commun       Date:  1987-07-15       Impact factor: 3.575

9.  Inhibition of mitochondrial respiration by analogs of 4-phenylpyridine and 1-methyl-4-phenylpyridinium cation (MPP+), the neurotoxic metabolite of MPTP.

Authors:  C L Hoppel; D Grinblatt; H C Kwok; P K Arora; M P Singh; L M Sayre; D Greenblatt
Journal:  Biochem Biophys Res Commun       Date:  1987-10-29       Impact factor: 3.575

10.  Energy-driven uptake of N-methyl-4-phenylpyridine by brain mitochondria mediates the neurotoxicity of MPTP.

Authors:  R R Ramsay; J Dadgar; A Trevor; T P Singer
Journal:  Life Sci       Date:  1986-08-18       Impact factor: 5.037

View more
  19 in total

1.  Depressant effect of mitochondrial respiratory complex inhibitors on proteasome inhibitor-induced mitochondrial dysfunction and cell death in PC12 cells.

Authors:  Sun-Joo Lee; Young Chul Youn; Eun Sook Han; Chung Soo Lee
Journal:  Neurochem Res       Date:  2005-09       Impact factor: 3.996

Review 2.  Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man.

Authors:  M Gerlach; P Riederer
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

3.  Characterization of brain beta-carboline-2-N-methyltransferase, an enzyme that may play a role in idiopathic Parkinson's disease.

Authors:  D A Gearhart; E J Neafsey; M A Collins
Journal:  Neurochem Res       Date:  1997-02       Impact factor: 3.996

4.  Harmine treatment enhances short-term memory in old rats: Dissociation of cognition and the ability to perform the procedural requirements of maze testing.

Authors:  Sarah E Mennenga; Julia E Gerson; Travis Dunckley; Heather A Bimonte-Nelson
Journal:  Physiol Behav       Date:  2014-09-22

5.  Exploiting the Polypharmacology of ß-Carbolines to Disrupt O. volvulus Molting.

Authors:  Major Gooyit; Nancy Tricoche; Sacha Javor; Sara Lustigman; Kim D Janda
Journal:  ACS Med Chem Lett       Date:  2015-01-20       Impact factor: 4.345

6.  Norharman-induced motoric impairment in mice: neurodegeneration and glial activation in substantia nigra.

Authors:  A Ostergren; A Fredriksson; E B Brittebo
Journal:  J Neural Transm (Vienna)       Date:  2005-08-03       Impact factor: 3.575

7.  Is complex II involved in the inhibition of mitochondrial respiration by N-methyl-4-phenylpyridinium cation (MMP+) and N-methyl-beta-carbolines?

Authors:  M J Krueger; A K Tan; B A Ackrell; T P Singer
Journal:  Biochem J       Date:  1993-05-01       Impact factor: 3.857

8.  Comparison of the in vitro binding characteristics of the beta-carbolines harman and norharman in rat brain and liver and in bovine adrenal medulla.

Authors:  T May; A Greube; S Strauss; D Heineke; J Lehmann; H Rommelspacher
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-03       Impact factor: 3.000

9.  Comparison of the Protective Effect of Indole beta-carbolines and R-(-)-deprenyl Against Nitrogen Species-Induced Cell Death in Experimental Culture Model of Parkinson's Disease.

Authors:  Young-Su Han; Jung-Mee Kim; Jeong-Seon Cho; Chung Soo Lee; Doo-Eung Kim
Journal:  J Clin Neurol       Date:  2005-04-30       Impact factor: 3.077

10.  Neuromelanin Modulates Heterocyclic Aromatic Amine-Induced Dopaminergic Neurotoxicity.

Authors:  Vivek Lawana; Se Young Um; Jean-Christophe Rochet; Robert J Turesky; Jonathan H Shannahan; Jason R Cannon
Journal:  Toxicol Sci       Date:  2020-01-01       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.